Knight Therapeutics Shareholders Approve All Proposals at Annual Meeting
Knight Therapeutics announced on May 12, 2022, the voting results from its Annual Meeting of Shareholders. All director nominees were elected, and external auditors and an employee share purchase plan were approved.
Montreal, Canada – Knight Therapeutics Inc. (TSX: GUD) announced on May 12, 2022, the voting results from its Annual Meeting of Shareholders. All nominees for the board of directors were elected.
Shareholders also voted to appoint Ernst & Young LLP as the corporation's external auditor for the upcoming year. The appointment of the audit firm received strong majority support.
Furthermore, a resolution regarding the approval of unallocated rights under the company's employee share purchase plan (ESPP) was put to a vote. Shareholders approved the plan's terms with approximately 79.41% of the votes cast.
Knight Therapeutics is a specialty pharmaceutical company focused on acquiring and commercializing pharmaceutical products for Canada and Latin America. The company's shares trade on the Toronto Stock Exchange under the symbol GUD.